1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,680 | 0,710 | 20:14 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Di | Instil Bio und ImmuneOnco lösen Lizenzvereinbarung auf | 7 | Investing.com Deutsch | ||
| Di | Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco | 4 | FierceBiotech | ||
| Di | IMMUNEONCO-B (01541): INSIDE INFORMATION - IMMUNEONCO TO REGAIN GLOBAL RIGHTS TO IMM2510 AND IMM27M | - | HKEx | ||
| Di | Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco | 109 | GlobeNewswire (Europe) | DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) ("Instil") today announced that Axion Bio, Inc. ("Axion"), a wholly-owned subsidiary of Instil, has decided to discontinue... ► Artikel lesen | |
| 03.12.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD | 5 | HKEx | ||
| 27.11.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE PHASE III CLINICAL STUDY PROTOCAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR ... | 1 | HKEx | ||
| 20.11.25 | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTIONS AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | 2 | HKEx | ||
| 17.11.25 | IMMUNEONCO-B (01541): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 17.11.25 | IMMUNEONCO-B (01541): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 07.11.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD | 2 | HKEx | ||
| 23.10.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM01 | - | HKEx | ||
| 16.10.25 | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 16.10.25 | IMMUNEONCO-B (01541): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 09.10.25 | BRIEF: ImmuneOnco to raise $45 million via share placement at 13% discount | 2 | Bamboo Works | ||
| 09.10.25 | IMMUNEONCO-B (01541): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 02.10.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM2510 | 2 | HKEx | ||
| 29.09.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF FOLLICULAR LYMPHOMA | - | HKEx | ||
| 23.09.25 | IMMUNEONCO-B (01541): 2025 INTERIM REPORT | 1 | HKEx | ||
| 26.08.25 | IMMUNEONCO-B (01541): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | - | HKEx | ||
| 18.08.25 | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE I CLINICAL TRIAL OF IMC-003/IMM72 | 3 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VENTYX BIOSCIENCES | 13,805 | +0,55 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,310 | +50,68 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,390 | +27,35 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 43,590 | -17,57 % | Regencell Bioscience is the top performing pharma stock YTD | ||
| ALUMIS | 17,950 | +0,17 % | What's Going On With Alumis Stock Thursday? | ||
| PRAXIS PRECISION MEDICINES | 291,71 | -0,28 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| PHATHOM PHARMACEUTICALS | 15,660 | -13,38 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| IMMUNEERING | 4,920 | -40,94 % | Immuneering Corporation: Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP | - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently... ► Artikel lesen | |
| EVOTEC | 6,338 | +0,76 % | EQS-News: Evotec SE: Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations
01.01.2026 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 25,500 | +9,54 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,29 | -0,11 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ERASCA | 5,140 | -0,58 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| RECURSION PHARMACEUTICALS | 4,740 | -2,47 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates | ||
| BIONTECH | 85,40 | -0,41 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen |
Das Unternehmen IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,740 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.